Of course, you must run Phase III since it doesn’t always match Phase II. In the case of Varegacestat, the Phase III data was very close to the Phase II data. PE: After presenting topline results from Phase 3 trials, what's next for Varegacestat? What’s standard is to put out topline data that is enough to tell the world what generally happened in the trial. For Varegacestat, we put out Phase III data in December.